Farnesyltransferase inhibitors and anti-Ras therapy
W. Wayt Gibbs(United States Military Academy), Allen Oliff(GlaxoSmithKline (United Kingdom)), George D. Hartman(Joint BioEnergy Institute), Samuel Graham(Georgia Institute of Technology), Laura Sepp‐Lorenzino(Intellia Therapeutics (United States)), Neal Rosen(Memorial Sloan Kettering Cancer Center), Kenneth S. Koblan(Sumitomo Dainippon Pharma (United States)), Michael W. Conner(United States Military Academy), Theresa M. Williams(United States Military Academy), Neville J. Anthony(United States Military Academy), Charles A. Omer(United States Military Academy), S. J. DESOLMS(Duke University), Nancy E. Kohl(United States Military Academy)
Cited by 42
Related Papers
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
|Cancer Research|2006|2.5k
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
|Nature|2010|1.8k
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
|New England Journal of Medicine|2021|1.7k
Ultrawide‐Bandgap Semiconductors: Research Opportunities and Challenges
|Advanced Electronic Materials|2017|1.5k